stem cells is the standard by which their pluripotent potential is evaluated. [1] [2] [3] We believe that the intended application of human induced pluripotent stem-cell lines should determine the evaluation method. The issue of pluripotency becomes important for studies of the functional mechanism of reprogramming. However, a reproducible and rapid method to determine the quality of newly established human pluripotent stem cells is urgently required. Perhaps an epigenetic and gene-expression signature that selectively defines fully reprogrammed pluripotent stem cells can be identified, since the variation of teratoma results brings up the question of this assay's value as a standard for proving pluripotency of human stem cells. 4 We tested our lines for the reactivation of endogenous pluripotency genes, the silencing of retroviral transgenes, and the capacity to form the three germ layers. In close collaboration with the pathology department, we are in the process of correlating the results of teratoma assays with the ability to generate functional cardiac myocytes. Although induced cardiomyocytes may replace pluripotent stem cells for disease modeling, this technique needs to be reproducibly established in human cells. Alessandra Moretti, Ph.D. Jason T. Lam, Ph.D. Karl-Ludwig Laugwitz, M.D.
Rapid Molecular Detection of Tuberculosis
To the Editor: Boehme et al. (Sept. 9 issue) 1 report encouraging results on the use of an automated molecular test for Mycobacterium tuberculosis and resistance to rifampin (Xpert MTB/RIF). However, the population of patients with clinical tuberculosis who have negative cultures still poses a problem of interpretation, which was not discussed in the article. Among study patients whose samples were culture-negative but who had symptoms of tuberculosis, 29.3% had positive results on the automated test; these patients made up 4.3% of the total number of automated test-positive patients.
In such patients, tuberculosis that was detected by the automated test may have had a false negative culture because of low bacillary load or overgrowth, but the possibility of false positivity cannot be excluded. Furthermore, 23 patients with nontuberculous mycobacteria in culture were excluded from the analysis. In our site in Tanzania and in other African locations, nontuberculous mycobacteria are frequently found in culture, 2, 3 so the capability of the automated test to discriminate between tuberculosis and nontuberculous mycobacteria, for which preliminary results have been encouraging, 4 would be of great interest. More effort should be made in future studies to elaborate on these two groups, thus clearing an uncertainty regarding the performance of the automated test. To the Editor: Although resistance to rifampin and isoniazid usually occurs concomitantly, rifampin monoresistance is known and well documented in certain populations. [1] [2] [3] When the automated test detects rifampin resistance, clinicians would have to consider further diagnostic and treatment options. First, would the strain be assumed to have multidrug resistance, given the high probability of concomitant resistance to isoniazid? In that event, treatment options would probably include the remaining first-line agents (ethambutol and pyrazinamide) plus a fluoroquinolone and an injectable antituberculosis agent. 4 Clinicians may still prescribe isoniazid until resistance to the drug is excluded. Further testing with the use of either a traditional assay or the Genotype MTBDRplus assay would still be needed. Nonetheless, at least one or more second-line agents would be initiated early in the treatment of the strain of tuberculosis with at least partial resistance. However, patients with rifampin monoresistance may be unnecessarily exposed to the untoward effects of injectable agents for tuberculosis until the complete drug-susceptibility pattern is obtained. Additional detection of isoniazid resistance would substantially enhance the utility of this test. Nitin Bhanot, M.D., M.P.H.
No potential conflict of interest relevant to this letter was reported. To the Editor: Boehme et al. report that an automated test for tuberculosis had a sensitivity of 97.6% and a specificity of 98.1% for the correct identification of patients with rifampin-resistant tuberculosis. Even though the test greatly advances the direct detection of M. tuberculosis, correct identification of rifampin-sensitive strains is essential, since the false diagnosis of multidrugresistant tuberculosis is deleterious for patients. 1 We have identified a patient with rifampinsensitive tuberculosis for whom automated testing of bronchoalveolar lavage falsely showed rifampin resistance. The M. tuberculosis bacterial load detected by the automated test was low. The curve pattern generated in the automated test resulted in the interpretation "rifampin resistance detected." In contrast, rpoB sequencing, 2,3 lineprobe testing (AID Diagnostika), repeated culture, and phenotypic drug-susceptibility testing revealed the presence of fully susceptible M. tuberculosis. In this patient, short-course therapy resulted in a clinical response.
A major limitation of the design of the automated test is that interpretation relies solely on a decreased level (or the absence) of wild-type beacon hybridization, rather than additional hybridization to mutant probes, which would add to the specificity of the test. Our results indicate that positive results for rifampin resistance on the automated test must be viewed with caution and should be confirmed by phenotypic or additional genotypic methods when possible. To the Editor: The study by Boehme et al., which reports a high degree of accuracy for an automated test for the identification of tuberculosis in adults, could revolutionize the diagnosis of tuberculosis globally. However, in high-burden settings, up to 30% of tuberculosis cases occur in children. The diagnosis in this age group is challenging, especially in the high-risk groups for disease progression and poor outcome, which include children who are under the age of 5 years, To the Editor: Rapid molecular detection of tuberculosis and isolated rifampin resistance may be cost-effective with some constraints. Such testing does not detect rifampin resistance caused by mutations outside the core region of the rpoB gene, and a single mutation might generate a different resistant phenotype. The presence of mutations within the rpoB locus that are not associated with resistance may influence the annealing properties of the probes. Thus, a substantial number of strains can be classified as resistant on genetic analysis and as sensitive on phenotypic testing. 1, 2 The efficiency of this nested polymerase-chainreaction (PCR) assay is ordinarily lowered when a reduced number of acid-fast bacilli (AFB) are encountered in sputum samples. Since the detection limit of such a system is generally 10 mycobacterial genome copies, sputum samples with a score of AFB 1+/rare may contain smaller amounts of required DNA to be amplified. 3 The study by Boehme et al. was conducted for 9 months. When used routinely for a long time, PCR assays can have false positive results because of amplicon or chromosomal DNA contamination. 4 Therefore, quality control and assurance is difficult in resource-poor countries in which tuberculosis is endemic. The genotyping method probably will not replace conventional phenotypic methods in the near future. Prasanta Raghab Mohapatra, M.D. We agree that the automated test can detect culture-negative tuberculosis, though quantifying this finding would have required a different study design. Specificity in culture-negative patients cannot be determined in those who are treated for tuberculosis on clinical grounds, since microbiologic follow-up is compromised. The high specificity we found for direct testing in more than 600 untreated patients (99.2%) is not surprising, since the test targets a tuberculosis-specific sequence, and analytic studies have not shown crossreactivity with 89 other pathogens or respiratory commensals. 2 Though heminested, the reaction takes place in a closed cartridge, and there have been no reports of amplicon contamination.
Bhanot and Mohapatra raise important questions concerning the use of testing for rifampin resistance in treatment decisions. Rifampin resistance is highly predictive of multidrug resistance in most settings. Furthermore, both multidrug-resistant and rifampin-monoresistant strains of tuberculosis are associated with poor treatment outcomes. Thus, rifampin resistance that is detected by the automated test would probably trigger treatment for multidrug resistance as well as expanded drug-susceptibility testing, depending on local epidemiologic factors.
Mohapatra is concerned about relying on mutations in the rpoB core region to detect rifampin resistance. Numerous studies have shown that this region encodes at least 95% of all rifampinresistant tuberculosis. 3 These studies are further supported by the clinical performance of Genotype MTBDRplus, which targets the same rpoB region as the automated test. 4 Mutations in this region almost always signify rifampin resistance. Recent reports suggest that certain rpoB core mutations identify rifampin resistance that is often missed by liquid-culture methods but that is still detected by testing on solid media. 5 We agree that genotypic testing will not replace phenotypic testing, at least in the short term, but will allow more rapid and decentralized detection of drug resistance.
Zbinden and colleagues are correct that although the specificity of the automated test for rifampin resistance was close to 100% in our study, rare false positive results for rifampin resistance have been reported subsequently by users. Such false calls would have special relevance in settings with a low prevalence of multidrugresistant strains. The selected assay format enables the detection of virtually all rifampin-resistance mutations. To resolve potential false calls, minor modifications are currently being made to the assay, which will further improve its overall accuracy for the detection of rifampin resistance.
Therapeutic Hypothermia after Cardiac Arrest
To the Editor: The midazolam dose of 0.15 mg per kilogram of body weight per hour described in the article by Holzer (Sept. 23 issue) 1 and in other articles on therapeutic hypothermia 2 is very similar to the recommended dose of midazolam used to adapt critically ill patients without neurologic problems to mechanical ventilation. 3 However, this dose may be excessive in comatose survivors of cardiac arrest who are undergoing therapeutic hypothermia; these patients probably
